Entera Bio Ltd. (ENTX)
Entera Bio Ltd. (ENTX) from its SEC filings: 2025 revenue $42,000 (-77% vs the year before), net margin -27236%, free cash flow -$7.5 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $42,000 |
| Revenue growth | -77% |
| Net income | -$11.4 million |
| Net margin | -27235.7% |
| Free cash flow | -$7.5 million |
| Diluted EPS | $0.25 |
| Cash | $11.3 million |
| Share count, 1 year | +279% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.